Cell

Immunotherapy

CD19

Biology

Interleukin 21

Antigen

Natural killer T cell

Cytotoxic T cell

In vitro

Immunology

T cell

Natural killer cell

Lymphokine-activated killer cell

Chimeric antigen receptor

Cancer research

Genetics

Immune system

New England Journal of Medicine

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors